Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621692 | 1.00 | SCD (0.38) | SCDKDM5BKCNK3P2RX3PDE10A | |
| SCHEMBL12285043 | 1.00 | SCD (0.38) | SCDKDM5BKCNK3P2RX3PDE10A | |
| SCHEMBL12183771 | 0.89 | SCD (0.34) | SCDKCNK3PDE10AEGLN1 | |
| SCHEMBL12183766 | 0.85 | KCNK3 (0.35) | SCDKCNK3 | |
| SCHEMBL2621695 | 0.83 | PDPK1 (0.46) | SCDKDM5BKCNK3PDE10APDPK1 | |
| SCHEMBL2621694 | 0.83 | PDPK1 (0.46) | SCDKDM5BKCNK3PDE10APDPK1 | |
| SCHEMBL12285714 | 0.83 | PDPK1 (0.46) | SCDKDM5BKCNK3PDE10APDPK1 | |
| SCHEMBL2621649 | 0.80 | KDM5A (0.43) | SCDKDM5BKCNK3PDE10AEGLN1 | |
| SCHEMBL12285807 | 0.80 | KDM5A (0.43) | SCDKDM5BKCNK3PDE10AEGLN1 | |
| SCHEMBL2621648 | 0.80 | KDM5A (0.43) | SCDKDM5BKCNK3PDE10AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | SCD 3867/4885KDM5B 827/4885KCNK3 2219/4885 |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | SCD 4831/4885KDM5B 553/4885KCNK3 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.